sur SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech: Unaudited results for the first nine months of 2024
Sartorius Stedim Biotech reported sales of €2,029 million for the first nine months of 2024, marking an organic decline of 3% at constant exchange rates. Recurring EBITDA amounted to €565 million with a margin of 27.8%, while net income was €129 million. The company benefited from a significant increase in orders for consumables, offsetting weak demand for equipment.
In the advanced therapies sector, the company experienced above-average growth. Revenue decreased by 1.9% compared to the previous year. The EMEA region posted a sales increase of 5.9%, while revenue decreased by 9.7% in the Americas.
Despite a cautious investment environment, the company expects to achieve its 2024 targets. It remains positive about its long-term outlook thanks to increasing approvals and the development of new biopharmaceutical treatments.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SARTORIUS STED BIO